Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $28.0 million.

  • Akebia Therapeutics' Free Cash Flow rose 51851.58% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.2 million, marking a year-over-year increase of 18349.94%. This contributed to the annual value of -$40.7 million for FY2024, which is 7401.64% down from last year.
  • Akebia Therapeutics' Free Cash Flow amounted to $28.0 million in Q3 2025, which was up 51851.58% from $22.2 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Free Cash Flow high stood at $33.8 million for Q3 2022, and its period low was -$70.8 million during Q1 2021.
  • Its 5-year average for Free Cash Flow is -$18.6 million, with a median of -$13.6 million in 2025.
  • As far as peak fluctuations go, Akebia Therapeutics' Free Cash Flow crashed by 37817.58% in 2024, and later soared by 51851.58% in 2025.
  • Akebia Therapeutics' Free Cash Flow (Quarter) stood at -$62.8 million in 2021, then rose by 12.94% to -$54.7 million in 2022, then surged by 95.78% to -$2.3 million in 2023, then plummeted by 93.59% to -$4.5 million in 2024, then surged by 727.31% to $28.0 million in 2025.
  • Its Free Cash Flow was $28.0 million in Q3 2025, compared to $22.2 million in Q2 2025 and -$13.6 million in Q1 2025.